Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller

Supply Chain Pain

Lessons from the earthquake in Japan show the vulnerability of the bio/pharma supply chain.
May 2, 2011

Lessons from the earthquake in Japan show the vulnerability of the bio/pharma supply chain.

A First Hand Look at India's Pharma Services Sector

Indian manufacturers are not a near-term threat to Western CMOs, but may be long term.
Apr 6, 2011

Indian manufacturers are not a near-term threat to Western CMOs, but may be long term.

A First-Hand Look at India's Pharma Services Sector

Indian manufacturers are not a near-term threat to Western CMOs, but may be long term.
Mar 2, 2011

Indian manufacturers are not a near-term threat to Western CMOs, but may be long term.

What to Watch for in 2011

CDMOs and CMOs face weak economic recovery, consolidation, and globalization.
Feb 2, 2011

CDMOs and CMOs face weak economic recovery, consolidation, and globalization.

The Preferred-Provider Model

The designation of preferred partners has become integral to the outsourcing process. Read this and other preferred organization articles in this special issue.
Feb 1, 2011

The designation of preferred partners has become integral to the outsourcing process. Read this and other preferred organization articles in this special issue.

Winning Big

Covance's deal with sanofi-aventis demonstrates the power of scale and scope.
Jan 5, 2011

Covance's deal with sanofi-aventis demonstrates the power of scale and scope.

What to Watch for in 2011

CDMOs and CMOs face weak economic recovery, consolidation, and globalization.
Jan 2, 2011

CDMOs and CMOs face weak economic recovery, consolidation, and globalization.

Winning Big

Covance's deal with sanofi-aventis demonstrates the power of scale and scope.
Dec 2, 2010

Covance's deal with sanofi-aventis demonstrates the power of scale and scope.

Buyers in Short Supply

Global pharmaceutical companies could have a problem getting rid of redundant facilities.
Nov 5, 2010

Global pharmaceutical companies could have a problem getting rid of redundant facilities.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here